{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:10Z","timestamp":1787671870078,"version":"build-2736575974"},"reference-count":50,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This phase 2 clinical study evaluated the efficacy and safety of post\u2013allogeneic hematopoietic stem cell transplantation maintenance cancer immunotherapy using 2 Wilms tumor 1 (WT1) peptide vaccines, MCI, for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years [range, 2-18]) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate (primary end point) was 70.6% (95% confidence interval [CI], 43.1-86.6); this rate was &amp;gt;30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders, who sustained complete remission at year 1 after the initiation of vaccination, had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7). WT1-specific cytotoxic T-cell (CTL) frequency in peripheral blood (PB) from all 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25% \u00b1 0.08%; after, 1.07% \u00b1 0.24%; P&amp;lt; .001), whereas WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12% \u00b1 0.2%; after, 0.20% \u00b1 0.25%; P = .424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a \u22651.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P = .027). Elevated WT1-specific CTL frequency in the PB before vaccination predicted the subsequent favorable patient prognosis. No patient discontinued treatment because of MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000005319.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019352","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:36:12Z","timestamp":1781717772000},"page":"5531-5542","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["WT1 peptide vaccines of post\u2013allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-274X","authenticated-orcid":false,"given":"Yoshiko","family":"Hashii","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Osaka International Cancer Institute, Osaka, Japan"},{"name":"2Department of Cancer Immunotherapy, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9171-6585","authenticated-orcid":false,"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[{"name":"3Department of Cancer Stem Cell Biology, The University of Osaka Graduate School of Medicine, Suita, Japan"},{"name":"4Department of Respiratory Medicine and Clinical Immunology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-3995","authenticated-orcid":false,"given":"Naoki","family":"Sakata","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Kindai University Faculty of Medicine, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Nakadori General Hospital, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-1184","authenticated-orcid":false,"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[{"name":"7Department of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-0947","authenticated-orcid":false,"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-2305","authenticated-orcid":false,"given":"Satoshi","family":"Hattori","sequence":"additional","affiliation":[{"name":"9Department of Biomedical Statistics, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-8819","authenticated-orcid":false,"given":"Hiroko","family":"Nakajima","sequence":"additional","affiliation":[{"name":"10Department of Cancer Immunology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7494-1204","authenticated-orcid":false,"given":"Jun","family":"Nakata","sequence":"additional","affiliation":[{"name":"7Department of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2433-510X","authenticated-orcid":false,"given":"Fumihiro","family":"Fujiki","sequence":"additional","affiliation":[{"name":"10Department of Cancer Immunology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-0455","authenticated-orcid":false,"given":"Soyoko","family":"Morimoto","sequence":"additional","affiliation":[{"name":"3Department of Cancer Stem Cell Biology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-8649","authenticated-orcid":false,"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"4Department of Respiratory Medicine and Clinical Immunology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Noguchi","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-1020","authenticated-orcid":false,"given":"Moeko","family":"Hino","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Chiba University School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"15Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"15Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"16Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-8825","authenticated-orcid":false,"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[{"name":"17Department of Pediatrics, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3182-2456","authenticated-orcid":false,"given":"Akihiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"2Department of Cancer Immunotherapy, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-2175","authenticated-orcid":false,"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"10Department of Cancer Immunology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"5","key":"2026082510522297300_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026082510522297300_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrc.2017.125","article-title":"Targeting minimal residual disease: a path to cure?","volume":"18","author":"Luskin","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2026082510522297300_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.2025028617","article-title":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Socie","year":"2025","journal-title":"Blood"},{"issue":"1-3","key":"2026082510522297300_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12026-010-8193-7","article-title":"Prevention of GVHD without losing GVL effect: windows of opportunity","volume":"49","author":"Zhang","year":"2011","journal-title":"Immunol Res"},{"issue":"22","key":"2026082510522297300_bib6","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.vaccine.2020.03.042","article-title":"Whole leukemia cell vaccines: past progress and future directions","volume":"38","author":"Ji","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"2026082510522297300_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21127","article-title":"Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia","volume":"83","author":"Kitawaki","year":"2008","journal-title":"Am J Hematol"},{"issue":"8","key":"2026082510522297300_bib8","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1038\/bcj.2013.29","article-title":"Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine","volume":"3","author":"Maeda","year":"2013","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026082510522297300_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbmt.2016.08.028","article-title":"Induction of immune response after allogeneic Wilms' tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and post-transplantation relapse","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10499","key":"2026082510522297300_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"2026082510522297300_bib11","doi-asserted-by":"crossref","first-page":"e004409","DOI":"10.1136\/jitc-2021-004409","article-title":"WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma","volume":"10","author":"van Amerongen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2026082510522297300_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"2026082510522297300_bib13","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"38","key":"2026082510522297300_bib14","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026082510522297300_bib15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood-2007-03-076844","article-title":"Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia","volume":"110","author":"Rezvani","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2026082510522297300_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/leu.2011.226","article-title":"WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission","volume":"26","author":"Hashii","year":"2012","journal-title":"Leukemia"},{"issue":"11-12","key":"2026082510522297300_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A\u22172402-binding residues","volume":"51","author":"Tsuboi","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2026082510522297300_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","article-title":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product","volume":"51","author":"Oka","year":"2000","journal-title":"Immunogenetics"},{"issue":"2","key":"2026082510522297300_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.coi.2008.04.009","article-title":"WT1 peptide vaccine for the treatment of cancer","volume":"20","author":"Oka","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"2026082510522297300_bib20","unstructured":"Japanese Society for Histocompatibility and Immunogenetics\n          . HLA-A alleles and corresponding antigens in the Japanese population, Tokyo. 2000 (in Japanese). Accessed 1 April 2008. https:\/\/jshi.smoosy.atlas.jp\/ja."},{"issue":"2","key":"2026082510522297300_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pbc.22522","article-title":"WT1 peptide immunotherapy for cancer in children and young adults","volume":"55","author":"Hashii","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026082510522297300_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3171\/JNS\/2008\/108\/5\/0963","article-title":"Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme","volume":"108","author":"Izumoto","year":"2008","journal-title":"J Neurosurg"},{"issue":"4","key":"2026082510522297300_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jjco\/hyl005","article-title":"A phase I\/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data","volume":"36","author":"Morita","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2026082510522297300_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08880010802435500","article-title":"WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report","volume":"26","author":"Ohta","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"issue":"12","key":"2026082510522297300_bib25","first-page":"1279","article-title":"Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan","volume":"46","author":"Miyawaki","year":"2005","journal-title":"Rinsho Ketsueki"},{"issue":"12","key":"2026082510522297300_bib26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2026082510522297300_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1705885","article-title":"Acute graft-versus-host disease in children","volume":"41","author":"Jacobsohn","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2026082510522297300_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2026082510522297300_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"issue":"3","key":"2026082510522297300_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2026082510522297300_bib31","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2026082510522297300_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","article-title":"Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026082510522297300_bib33","doi-asserted-by":"crossref","first-page":"782785","DOI":"10.3389\/fped.2021.782785","article-title":"Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy","volume":"9","author":"Truong","year":"2021","journal-title":"Front Pediatr"},{"issue":"4","key":"2026082510522297300_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1349-7006.2009.01468.x","article-title":"High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ","volume":"101","author":"Murao","year":"2010","journal-title":"Cancer Sci"},{"issue":"2","key":"2026082510522297300_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00262-018-2274-1","article-title":"A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma","volume":"68","author":"Tsuboi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2026082510522297300_bib36","first-page":"32","article-title":"An analysis of 19 patients with recurrent lymphocytic malignant disease treated by the ALL-RDX BFM87 protocol","volume":"15","author":"Kitazawa","year":"2001","journal-title":"Jpn J Pediatr Hematol"},{"issue":"9","key":"2026082510522297300_bib37","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3324\/haematol.12807.","article-title":"Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?","volume":"93","author":"Goemans","year":"2008","journal-title":"Haematologica"},{"issue":"1 suppl","key":"2026082510522297300_bib38","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.bbmt.2010.11.009","article-title":"Graft versus leukemia reactivity after allogeneic stem cell transplantation","volume":"17","author":"Falkenburg","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2026082510522297300_bib39","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/bloodadvances.2020004073","article-title":"Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI","volume":"5","author":"Schultze-Florey","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2026082510522297300_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2011.01.001","article-title":"Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia","volume":"39","author":"Kitawaki","year":"2011","journal-title":"Exp Hematol"},{"issue":"10","key":"2026082510522297300_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2026082510522297300_bib42","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1038\/s41467-019-13438-1","article-title":"CD4(+) T cell help creates memory CD8(+) T cells with innate and help-independent recall capacities","volume":"10","author":"Ahrends","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"2026082510522297300_bib43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4(+) T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1-2","key":"2026082510522297300_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2026082510522297300_bib45","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2026082510522297300_bib46","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"2026082510522297300_bib47","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s00277-025-06325-x","article-title":"Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia","volume":"104","author":"Stock","year":"2025","journal-title":"Ann Hematol"},{"issue":"1","key":"2026082510522297300_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"7","key":"2026082510522297300_bib49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/bmt.2009.327","article-title":"Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children","volume":"45","author":"Watanabe","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2026082510522297300_bib50","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1182\/blood-2011-04-349068","article-title":"Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease","volume":"118","author":"Jacobsohn","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2026082510522297300_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood.V124.21.672.672","article-title":"Clinical phase II study of WT1 peptide vaccination in pediatric leukemia patients after stem cell transplantation and analysis of immunological monitoring","volume":"124","author":"Hashii","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5531\/2537432\/blooda_adv-2025-019352-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5531\/2537432\/blooda_adv-2025-019352-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:58:06Z","timestamp":1787669886000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5531\/569156\/WT1-peptide-vaccines-of-post-allogeneic-HSCT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":50,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019352","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,12]]}}}